Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2019

View Archived Issues

IKK-alpha and BRAF kinases implicated in DNA damage response can be targeted in cancer

Integrin alphaVbeta6 found to be an effective target for pancreatic ductal adenocarcinoma therapy

TRPV1 as a novel therapeutic target in type 2 diabetes mellitus

GM1 ganglioside is protective in alpha-synuclein model of Parkinson's disease

Shanghai Yingli Pharmaceutical identifies TGF-beta receptor type-1 inhibitors

Oxford University Innovation discloses RAS-effector protein interaction inhibitors

Enhancement of neuronal M-Type K+ currents prevents brain damage following traumatic brain injury

Mitochondrial metabolism promotes proteasome inhibitor resistance and sensitivity to elesclomol

Redx Pharma presents Rho-associated protein kinase inhibitors

LEF1 overexpression implicated in esophageal squamous cell carcinoma via TGF-beta signaling

Neutrophil extracellular traps help gallstones form

NFKBIL1 gene polymorphisms linked to autistic-like traits

Fujimoto Pharmaceutical describes new TNF-alpha production inhibitors

Microbiome boosts host defense against chlamydia

Medscienta presents new antiatherosclerotic agents

FDA approves Rinvoq for the treatment of moderate to severe rheumatoid arthritis

FDA approves the first new treatment in nearly a decade for patients with myelofibrosis

Scancell provided update on phase II study of SCIB-1 in patients with advanced melanoma

Recruitment ongoing in Janssen's first-in-human study of JNJ-74699157

Patient recruitment initiated in phase II study of TQ-B3101 in ROS1-positive NSCLC

Bird Rock Bio initiates phase II study of nimacimab in patients with diabetic gastroparesis

Fulcrum Therapeutics initiates phase IIb ReDUX4 study of losmapimod in FSHD

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...